Medscape1d
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Renal & Urology News18d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...
Monthly Prescribing Reference13d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...
Medscape16h
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Yahoo Finance13d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
Monthly Prescribing Reference1mon
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
The active GLP-1 RA prescription group had a significantly lower risk for 30-day readmission and 180-day postoperative wound dehiscence and postoperative hematoma after matching. HealthDay News ...